Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery

HIV drugs struggle to reach viral reservoirs hidden deep inside tissues like the lymph nodes and brain, allowing the virus to persist even when blood tests show undetectable levels. Researchers at the University of Liverpool are engineering nanoparticles to carry antiretroviral drugs directly into these hard-to-reach sanctuaries. The core problem is that conventional HIV medications, while effective in the bloodstream, cannot cross biological barriers such as the blood-brain barrier or penetrate dense lymphoid tissue. This leaves pockets of active virus that can reignite infection if treatment stops. The new nanomedicine approach wraps drugs in tiny lipid or polymer shells designed to slip past these barriers and release their payload precisely where the virus hides. If successful, the technology could transform HIV from a lifelong daily pill regimen into a treatment that requires far fewer doses—potentially a monthly injection—while reducing the risk of drug resistance and viral rebound. The project builds on the team’s existing nanoparticle platforms and includes a public engagement plan to discuss the implications of long-acting HIV therapies. This is applied nanomedicine development, not fundamental science; the goal is a practical delivery system ready for preclinical testing.